You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Select search scope: search across all journals or within the current journal

Search this journal

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

All content on this site: Copyright © 2026 Sage Publications. All rights reserved. This website is technically supported and operated by China National Publications Import and Export (Group) Co., Ltd. 京ICP备09090397号-11

Comment: pathophysiology of mifepristone-induced septic shock due to Clostridium sordellii

Annals of Pharmacotherapy

Impact Factor: 2.3 / 5-Year Impact Factor: 2.7

Journal Homepage Submission guidelines

Restricted access

Letter

First published online December, 2005

Comment: pathophysiology of mifepristone-induced septic shock due to Clostridium sordellii

and

Volume 39, Issue 12

https://doi.org/10.1345/aph.1G189a

Abstract

Get full access to this article

View all access options for this article.

References

1.

1. Miech

RP.

Pathophysiology of mifepristone-induced septic shock due to Clostridium sordelii. Ann Pharmacother 2005;39:1483–8. Epub 26 Jul 2005. DOI 10.1345/aph.1G189.

2.

2. Gupta

K

Hillier

SL

Hooton

TM

Roberts

PL

Stamm

WE.

Effects of contraceptive method on the vaginal microbial flora: a prospective evaluation. J Infect Dis 2000;181:595–601.

Browse journal

Current issue OnlineFirst All issues

Similar articles

Retricted access

Cataract Surgery Under Infliximab Therapy in a Patient With Behçet’s Disease

Retricted access

Pharmacological evaluation of methanolic leaf extract of Swietenia mahagoni on acrylamide-induced neuropathic pain in rats

Retricted access

Effect of Aminoguanidine on the Conjunctival Histamine and Nitrite Levels in Experimental Conjunctivitis

Retricted access

Two-Year Outcome of Intravitreal Injections of Ranibizumab for Myopic Choroidal Neovascularization